Blog

Cell Line Development Planning in an Unsettled Budget Year

Cell Line Development Planning in an Unsettled Budget Year Cell line development planning depends on dates, and several federal dates remain open. NIH notice NOT-OD-26-131 puts the agency under a continuing resolution through December 11, 2026. That resolution holds funding at fiscal 2026 enacted levels. Institutes may also issue non-competing awards below the level on … Continue reading Cell Line Development Planning in an Unsettled Budget Year

Immunoassay Reagent Production as Blood Tests Reach Primary Care

Immunoassay Reagent Production as Blood Tests Reach Primary Care Immunoassay reagent production rarely makes headlines, yet it sits beneath every blood-based diagnostic. On November 10, 2026, Roche previewed new blood-test data for CTAD 2026, the Alzheimer’s congress meeting November 16 to 19 in Boston. The company describes its Elecsys pTau217 test as suitable for primary … Continue reading Immunoassay Reagent Production as Blood Tests Reach Primary Care

Insect Cell Expression in Recombinant Protein Programs

Insect Cell Expression in Recombinant Protein Programs Insect cell expression returned to the news on October 29, 2026. Novavax announced a $125 million milestone after the fifth patient was dosed in Sanofi’s Phase 3 influenza-COVID-19 combination trial in Europe. Those deal terms are company-reported. Still, the antigen inside that study comes from insect cells, and … Continue reading Insect Cell Expression in Recombinant Protein Programs

Integrated Protein Production: Where Program Time Actually Goes

Integrated Protein Production: Where Program Time Actually Goes Integrated protein production moved up the buyer agenda this fall. On October 12, 2026, Research and Markets projected that the contract manufacturing and research services market will grow from $303.8 billion in 2026 to $472.1 billion by 2033. That summary credits integrated services with shorter timelines. Consequently, … Continue reading Integrated Protein Production: Where Program Time Actually Goes

Cell Bank Resilience as Biomanufacturing Becomes Critical Infrastructure

Cell Bank Resilience as Biomanufacturing Becomes Critical Infrastructure Cell bank resilience entered the policy conversation this fall. On September 24, 2026, lawmakers introduced the Protecting Biotechnology and Biomanufacturing as Critical Infrastructure Act (H.R. 10569). The bill would direct the Cybersecurity and Infrastructure Security Agency to protect biomanufacturing infrastructure. Consequently, buyers are asking sharper questions about … Continue reading Cell Bank Resilience as Biomanufacturing Becomes Critical Infrastructure